AACR 2023 – Moderna's immunotherapeutic splash
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
Pfizer rescues biotech
The $43bn deal for Seagen marks the biggest biopharma acquisition since the pre-crash takeouts of Allergan and Celgene.
ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise
The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.
